Incannex Submits IND Application To The U.S. FDA For IHL-42X For Obstructive Sleep Apnoea
Portfolio Pulse from Happy Mohamed
Incannex Healthcare Limited (NASDAQ:IXHL) has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for IHL-42X, a treatment for obstructive sleep apnoea. The IND application includes comprehensive information on the safety and efficacy of IHL-42X, as well as details on the development, manufacturing, quality, and stability of the drug product. The application also outlines the clinical trial protocol for a multi-site phase 2/3 clinical trial investigating IHL-42X.
July 21, 2023 | 1:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incannex's submission of an IND application to the FDA for IHL-42X could potentially lead to regulatory approval and the commencement of clinical trials. This could have a positive impact on the company's stock in the short term.
The submission of an IND application is a crucial step in gaining regulatory approval and conducting clinical trials. If the FDA approves the application, it could lead to increased investor confidence in Incannex and a potential rise in its stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100